HighTower Advisors
BIO icon

HighTower Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

HighTower Advisors’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-400
Closed -$35K – 3170
2022
Q2 		$35K Buy
+400
New +$208K ﹤0.01% 2950

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

HighTower Advisors's BIO Position: Q2 2026 in Review

HighTower Advisors reduced its Bio-Rad Laboratories Class A (BIO) stake by 47% in Q2 2026, selling an estimated $682K and leaving 2,720 shares worth $799K. The position accounts for ﹤0.01% of the portfolio, ranked #2380.

HighTower Advisors first reported a position in BIO in Q4 2015 and has held it in 39 quarters since. The position peaked at $5.38M in Q4 2021. 398 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • HighTower Advisors held 2,720 shares of Bio-Rad Laboratories Class A worth $799K as of Q2 2026.
  • HighTower Advisors sold 2,404 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $682K.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #2380 holding.
  • HighTower Advisors first reported a position in Bio-Rad Laboratories Class A in Q4 2015 and has held it in 39 quarters since.
  • HighTower Advisors's Bio-Rad Laboratories Class A position peaked at $5.38M in Q4 2021.
  • 398 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.